If you have traveled to any area in the US that is considered a “hot spot” with increasing amount of cases of COVID please alert our office before coming in for any appointment. All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. FOR THE LATEST UP TO DATE INFORMATION, ALERTS AND CANCELLATIONS PLEASE CLICK HERE

Mitul Gandhi, MD

VCS Physicians

Mitul Gandhi, MD Headshot

I am mindful of how life altering a diagnosis of cancer can be, not just for the patient, but all the loved ones in their life as well. Patients and families rightly deserve, and will always get the very best of us in intelligence and compassion, along with access to state of the art treatment which is continually improving long-term outcomes.

Work and Credentials:

Primary Location

Gainesville Office

Position

Medical Oncologist

Board Certification

Medical Oncology, Hematology, and Internal Medicine

Fellowship

Northwestern University Feinberg School of Medicine, Medical Oncology and Hematology

Internship

University of Michigan Health System

Residency

University of Michigan Health System

Medical School

Rutgers Robert Wood Johnson Medical School

College

Rutgers University

Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University of Michigan Health System.

Dr. Gandhi joins Virginia Cancer Specialists after serving as Chief Fellow in the Medical Oncology and Hematology Fellowship program at Northwestern University Feinberg School of Medicine. During his time at Northwestern, Dr. Gandhi actively participated in clinical research, with a focus in high risk lymphoma. He has presented at major national meetings, won the American Society of Hematology’s Abstract Achievement Award in 2013, and has several publications including a recent article in Blood on double hit lymphomas. Dr. Gandhi is currently an Associate Member of both the American Society of Hematology and the American Society of Clinical Oncology.

In his spare time, Dr. Gandhi enjoys traveling with his wife, reading and writing, and spending time with family and friends.



 

Practice Blog

September 6, 2017

Mitul Gandhi, MD

Read More
June 15, 2020

Dr. Mitul Gandhi, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma

Read More
May 20, 2020

Practice Message Covid19 and Cancer: Cancer Doesn't Stop in a Pandemic

Read More

Physician Publications

June 15, 2020

Dr. Mitul Gandhi, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma

Read More
May 20, 2020

Practice Message Covid19 and Cancer: Cancer Doesn't Stop in a Pandemic

Read More
February 15, 2016

Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.

Read More

More Publications by Mitul Gandhi, MD

May 1, 2014

Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse

Read More
April 22, 2014

Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.

Read More
February 13, 2014

Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.

Read More
November 15, 2013

Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)

Read More
January 7, 2013

Association of implantable defibrillator therapy risk with body mass index in systolic heart failure

Read More
January 1, 2013

Brentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma

Read More

Clinical Trials (3)

Clinical Trial 19247

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)


Clinical Trial 18013

SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects .  Ph2 A+AVD +G-CSF or AOAD in CHL


Clinical Trial 19205

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)(U2-VEN-207)

Primary Location

Gainesville Office Office

Gainesville Office

Learn More

Other Locations

Awards

November 1, 2019

2019 Washingtonian Magazine Top Doctors


January 1, 2019

Northern Virginia Magazine Top Doctor 2019


January 1, 2018
Northern Virginia Magazine Top Doctors 2018

Northern Virginia Magazine Top Doctors 2018


January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination


September 20, 2020